BMY Stock Price Today (July 2026) — Bristol-Myers Squibb Company Analysis & Key Metrics 2026-07-17
Bristol-Myers Squibb Company (BMY) is trading at $60.74, up 0.38% today (as of July 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $63.08 (3.9% upside).
- Volatility remains elevated (32.89% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (2.60% YoY) alongside significant competitive pressures.
BMY Stock Analysis: Key Metrics & Valuation (July 2026)
Concise, actionable data for investors
Bristol-Myers Squibb Company - Historical Price & Volume
Market Cap
Enterprise Value: $153.64B
P/E Ratio
Forward P/E: 9.31
Revenue Growth
Year over Year
Analyst Target
+3.9% upside potential
Key Investor Questions About BMY
What investors need to know before buying
Based on current market data, BMY presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 63.86)
- Fundamentals say: Caution warranted (high leverage concerns)
BMY's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for BMY investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $46.43B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, BMY stock traded between $42.52 and $62.89—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 32.89% annualized volatility and β=0.28, the stock exhibits low sensitivity to market moves—making BMY suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
The Real Question Buried Inside Merck Stock's Premium Price
The drugmaker looks expensive today, but the real story is what you are actually paying for the earnings of tomorrow.
Why the Market Dipped But Bristol Myers Squibb (BMY) Gained Today
Bristol Myers Squibb (BMY) reached $60.48 at the closing of the latest trading day, reflecting a +2.99% change compared to its last close.
Why Is The Market Punishing JNJ Stock?
The pharma division is firing on all cylinders, but a sudden crack in the MedTech business has the market worried about the company's new two-part growth plan.
Bristol Myers Squibb (BMY) Wins FDA Review For Mezigdomide In Multiple Myeloma
FDA has accepted Bristol Myers Squibb's New Drug Application for mezigdomide in combination with carfilzomib and dexamethasone for relapsed or refractory multiple myeloma. The filing is supported by a Phase 3 trial that showed a meaningful improvement in progression free survival for this patient group. This decision marks a key regulatory milestone for NYSE:BMY's oncology pipeline and could influence how investors view its future revenue mix. Bristol-Myers Squibb enters this news cycle...
Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report?
Bristol Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Eli Lilly-Backed Novel Cancer Therapy Firm Raises $315 Million
(Bloomberg) -- AdvanCell Pty, a biotechnology firm backed by Eli Lilly & Co., has raised $315 million in new funding, underscoring investor confidence in its experimental cancer therapy.Most Read from BloombergThailand Scraps Plan to End Visa-Free Entry for Indian TouristsTrump Drops 20% Fee for Hormuz Cargo After Gulf PressureUS Hits Iran With Strikes, Blockade as Trump Plans Hormuz ChargeOpenAI’s First Device Will Be Movable, Screenless Speaker Built as AI Companion‘We Faltered’: IBM Plunges M
Can BMY's CELMoD Program Advancements Strengthen Its Oncology Portfolio?
BMY's FDA filing for mezigdomide in relapsed or refractory multiple myeloma marks another step in advancing its protein degrader pipeline.
Donald Trump's Drug-Pricing Deals Are Reshaping Big Pharma -- Here's What That Means for Pfizer, AbbVie, and Bristol Myers Squibb
Drug pricing matters, but pipelines matter even more.
Own Regeneron For Biotech Growth? Incyte Is Making Its Case.
For investors seeking exposure to biotechnology's future, Incyte presents a clearer forward picture of accelerating growth, while the larger Regeneron asks for more faith in its pipeline.
Frequently Asked Questions
Common investor questions about Bristol-Myers Squibb Company
Bristol-Myers Squibb Company (BMY) is currently trading at $60.74. The RSI (14-day) is at 63.9, indicating neutral territory. Wall Street analysts have a consensus "Hold" recommendation. The mean analyst price target of $63.08 implies 3.9% upside from current levels. Volatility is moderate at 32.9% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Bristol-Myers Squibb Company (BMY): The trailing P/E ratio is 17.01, which is in line with broader market averages. The forward P/E is 9.31, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 1.50, near 1.0, suggesting roughly fair value relative to growth. Price-to-Book is 6.18. Price-to-Sales is 2.56. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 25 analysts covering BMY, the consensus price target is $63.08. This represents a 3.9% upside from the current price of $60.74. The range spans from a low target of $40.00 to a high target of $75.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "Hold". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Bristol-Myers Squibb Company (BMY) pays a dividend with a current yield of approximately 4.15%. The annualized dividend rate is $2.50 per share. The payout ratio is 70.0%, which is moderate and suggests adequate earnings coverage for the dividend. The most recent ex-dividend date was 2026-07-02T00:00:00.000Z.
Key risks for Bristol-Myers Squibb Company (BMY) investors include: 1. Moderate volatility (32.9% annualized)—price swings are notable. 2. Elevated debt levels (D/E ratio of 230.97) which could pressure margins in a rising rate environment. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Bristol-Myers Squibb Company's (BMY) current debt and financial health profile: Total debt stands at $46.43B. The debt-to-equity ratio is 230.97, which is high and could pose financial risk if earnings decline or borrowing costs increase. The current ratio is 1.42, indicating adequate short-term liquidity. The quick ratio is 1.18. The company holds $10.49B in cash and equivalents. Free cash flow is positive at $9.85B, providing a cushion for debt servicing and shareholder returns.